Hier finden Sie den Zugang zur Notfallseite, Kontaktinformationen, Barrierefreiheits-Einstellungen, die Sprachwahl und die Suchfunktion.

Navigation öffnen

MRI Core Lab

MRI Core Lab Berlin is a cardiovascular image analysis center for scientific research investigations in clinical trials with imaging endpoints. At the lab four dedicated cardiac MRI scanners from two different vendors (Philips 1.5 and 3.0 Tesla and Siemens 1.5 and 3.0 Tesla) allow us to simultaneously acquire cMRIs using the MRI Core Lab function. Founded in 1996, the MRI Core Lab currently performs more than 6,000 clinical cardio-vascular MRI scans each year.

Sie befinden sich hier:


Participation in trial / substudy design

We provide assistance in the development of:

  • clinical study protocols and ancillary imag-ing studies
  • harmonized echocardiographic and cMRI substudies
  • eCRF (electronic case report forms)
  • cardiac MRI manual
  • study analysis plan
  • study specific standard operation proce-dures (SOPs) for data handling and analy-sis

Offline vendor independent analysis

All cMRIs will be analyzed offline with the FDA/NIH approved vendor independent analysis platform QMass Medis (at German Heart Institute Berlin) or CVI42 (at Charité, Campus Buch). This software analyzes cardiac MRI scans acquired with GE, Siemens, Philips and Toshiba MRI scanners; the software offers morphological and functional anal-ysis including novel parameters e.g. strain and extracellular volume and diffuse myocardial fibro-sis.

Certified data management (provided by IT de-partment of German Heart Institute Berlin)

Services include:

  • 24h support
  • web-based data collection platform for receiving imaging data from sites
  • Optional manual CD/DVD import by technician
  • pseudonymization of incoming DICOM data
  • initial technical check-up routine
  • query management
  • reporting
  • providing eCRFs for collecting analysis results

Conventional cardiac MRI parameters include:

  • LV and RV mass; LA volume and size, LV and RV volumes at ES/ED;
  • LV and RV ejection fraction; LVESD; LVEDD; LV wall thickness
  • RV function and RV mass
  • myocardial fibrosis (late stage); inflamma-tion (T2-weighted images)
  • assessment of pericardium
  • ischemia – perfusion and wall motion analysis
  • quantification of late gadolinium enhan-cement

Novel cardiac MRI parameters

  • LV, LA, RV strain and strain rate (longitudi-nal and circumferential)
  • parametric mapping (T1 and T2 mapping of the LV)
  • diffuse myocardial fibrosis (extracellular volume); collagen volume fraction
  • RV longitudinal strain and strain rate
  • vascular function: pulse wave velocity and wall shear stress (aorta)

Training services

Training services
detailed CMR manual
detailed SOPs for image acquisition
hands-on training during study kick-off meetings
CMR site certification
Follow-up online training as necessary


hardware: 1.5 and 3.0 T Philips MRI (equipped for clinical and research use in humans and small animals, including spectroscopy)

software: Philips; Medis (FDA approved); TomTec; MatLab; CVI.42

education/certification: CMR Academy (courses, fellowships) EACVI / SCMR / DGK (up to level III); Berlin Chamber of Physicians (12 months)

extensive experience in MRI multicenter trials (phase I, IIa, b; III and IV)

cooperation with Philips Healthcare; Sie-mens, Bayer Healthcare, Schering, Epix, Bracco, Biotronic, SJM, Medis, TomTec

publications: >300 original articles

experience: 20+ years

Ongoing Trials

Serelaxin in experimental heart failure: an in vivo serial MRI and biochemical analysis (ongoing)

Selective decrease of C-reactive protein using CRP-apheresis in patients with acute myocardial infarction.(ongoing)

COMeDY-Study (colchicine for the treatment of inflammatory cardiomyopathy (in preparation)

Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance im-aging (published: Kelle S et al. JACC 2009)

A bi-center cardiovascular magnetic resonance prognosis study focusing on dobutamine wall mo-tion and late gadolinium enhancement in 3,138 consecutive patients (published: Kelle S et al. JACC 2013)

Effect of renal denervation on left ventricular mass and function in patients with resistant hyperten-sion: data from a multi-centre cardiovascular magnetic resonance imaging trial (published: Mahfoud F et al. EHJ 2014)

NIH-Trial (Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, ob-servational study of hypertrophic cardiomyopathy.) (Germany: lead by J. Schulz-Menger)

CMR Bayer Trial "GadaCAd" (Germany: lead by J. Schulz-Menger)

Key Publications

Doltra A et al. JAHA 2014; Potential Reduction of Interstitial Myocardial Fibrosis With Renal Denerva-tion.

Hays AG et al. Circulation CVI 2012; Regional Coronary Endothelial Function Is Closely Related to Local Early Coronary Atherosclerosis in Patients With Mild Coronary Artery Disease.

Kelle S et al. JACC 2009; Prognostic Value of Myo-cardial Infarct Size and Contractile Reserve Using Magnetic Resonance Imaging.

Kelle S et al. Am J Cardiol 2011; Coronary Artery Distensibility Assessed by 3.0 Tesla Coronary Magnetic Resonance Imaging in Subjects With and Without Coronary Artery Disease.

Mahfoud F et al; Eur Heart J 2014; Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial.

Schneeweis C et al. PLOS One 2012; Delayed Contrast-Enhanced MRI of the Coronary Artery Wall in Takayasu Arteritis.

Kelle S et al. JACC 2013; A bi-center cardiovas-cular magnetic resonance prognosis study focu-sing on dobutamine wall motion and late gadolini-um enhancement in 3,138 consecutive patients.

Liu CY et al. JACC 2013; Evaluation of Age-Related Interstitial Myocardial Fibrosis With Cardiac Mag-netic Resonance Contrast-Enhanced T1 Mapping MESA (Multi-Ethnic Study of Atherosclerosis).

Gebker R et al. Radiology 2008; Diagnostic Per-formance of Myocardial Perfusion MR at 3 T in Patients with Coronary Artery Disease.

Moon JC et al. JACC 2013; T1 Mapping for Diffuse. Myocardial Fibrosis A Key Biomarker in Cardiac Disease?

Gebker R et al. JCMR 2011; The role of dobutami-ne stress cardiovascular magnetic resonance in the clinical management of patients with suspected and known coronary artery disease.

Messroghli DR et al. Radiology 2006; Human myo-cardium: single-breath-hold MR T1 mapping with high spatial resolution - reproducibility study.

Messroghli DR et al. Radiology 2005; Assessment of regional left ventricular function: accuracy and reproducibility of positioning standard short-axis sections in cardiac MR imaging.

Messroghli DR et al. Circulation CVI 2011; Asses-sment of Diffuse Myocardial Fibrosis in Rats Using Small-Animal Look-Locker Inversion Recovery T1 Mapping


PD Dr. Sebastian Kelle (MD, PhD, FESC)

German Heart Institute Berlin
Department of Internal Medicine/Cardiology
Augustenburgerplatz 1
13353 Berlin

t: +49 30 4593 2400
f: +49 30 4593 2500